21. SAT0174 Efficacy of Sarilumab plus csDMARDs in Rheumatoid Arthritis Patients Who Had An Inadequate Response To One or More than One Prior TNF Inhibitor. (15th July 2016) Authors: Genovese, M.C.; Pinheiro, G.da R.C.; Mangan, E.K.; Lin, Y.; van Adelsberg, J.; van Hoogstraten, H.; Thompson, D.; Fleischmann, R. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 730 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. SAT0185 Clinical and Radiographic Efficacy of Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Rheumatoid Arthritis in a Phase 3, Randomized, Double-Blind, Placebo-Controlled International Study. (9th June 2015) Authors: van der Heijde, D.; Genovese, M.C.; Fan, C.; Fiore, S.; Decktor, D.L.; Fleischmann, R. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. SAT0198 Effect of Increased Sarilumab Dose on Efficacy and Safety Outcomes in Poorly Responding Rheumatoid Arthritis (RA) Patients: The Mobility Study. (9th June 2015) Authors: Genovese, M.C.; Decktor, D.L.; Parrino, J.; Boddy, A.; Graham, N. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 727 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. SAT0341 Efficacy and safety of ixekizumab in patients with active psoriatic arthritis and previous inadequate response to tnf inhibitors: 52-week results from a phase 3 study. (12th June 2018) Authors: Genovese, M.C.; Combe, B.; Kremer, J.; Adams, D.; Lee, C.; Kerr, L.; Nash, P. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors. (9th June 2015) Authors: Smolen, J.S.; Kremer, J.; Gaich, C.; DeLozier, A.M.; Schlichting, D.; Xie, L.; Genovese, M.C. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 785 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. SAT0404 Fifty-Two Week Clinical Response to Brodalumab, an Anti-IL-17R Antibody, in Subjects with Psoriatic Arthritis. (10th June 2014) Authors: Mease, P.J.; Genovese, M.C.; Greenwald, M.W.; Ritchlin, C.T.; Beaulieu, A.; Deodhar, A.; Newmark, R.; Feng, J.; Erondu, N.; Nirula, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 740 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. THU0101 Tissue metabolite of type i collagen, c1m, and crp predicts structural progression of rheumatoid arthritis. (12th June 2018) Authors: Bay-Jensen, A.C.; Platt, A.; Jenkins, M.; Weinblatt, M.; Byrjalsen, I.; Musa, K.; Genovese, M.C.; Karsdal, M.A. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 272 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. THU0133 Results from A Phase 2A, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of Jnj-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-Modifying Antirheumatic Drug Therapy. (10th June 2014) Authors: Genovese, M.C.; Hsia, E.; Belkowski, S.; Chien, C.; Masterson, T.; Thurmond, R.; Manthey, C.; Yan, D.; Ge, T.; Greenspan, A. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 224 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. THU0138 Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An Adalimumab Biosimiar) with Adalimumab Reference Product in Patients with Moderate To Severe Rheumatoid Arthritis despite Methotrexate Therapy. (15th July 2016) Authors: Kay, J.; Weinblatt, M.; Keystone, E.; Genovese, M.C.; Baranauskaite, A.; Cheong, S.Y.; Ghil, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study. (15th July 2016) Authors: Choe, J.-Y.; Smolen, J.S.; Keystone, E.; Genovese, M.C.; Choi, J.; Rho, Y.H. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗